20420844|t|Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.
20420844|a|Alzheimer's disease (AD) is a progressive neurodegenerative disorder and is the most common form of dementia in elderly people. The accumulation of amyloid beta (Abeta) is one of the histopathological hallmarks of AD. Abeta is aggregated to form oligomers which are toxic to neurons and are critical to the onset and progression of AD. In a Caenorhabditis elegans (C. elegans) model of AD, human Abeta is expressed intracellularly in the body wall muscle. The expression and subsequent aggregation of Abeta in the muscle lead to progressive paralysis. Although the mechanism of action is unknown, antidepressants have been used with FDA approved drugs for dementia in AD and have been shown to enhance cognitive function in human and in animal models of AD. We found that the antidepressant fluoxetine, a selective serotonin reuptake inhibitor, significantly delayed Abeta-induced paralysis in the C. elegans model of Abeta toxicity by reducing Abeta oligomers. Our results showed that insulin signaling and DAF-16/FOXO transcription factors were required for fluoxetine-mediated delayed paralysis. We also found that fluoxetine increased thermal stress resistance and extended life span. These findings suggests that fluoxetine may have benefit for the treatment of AD by the reduction of proteotoxicity.
20420844	0	10	Fluoxetine	Chemical	MESH:D005473
20420844	63	69	daf-16	Gene	172981
20420844	106	128	Caenorhabditis elegans	Species	6239
20420844	130	149	Alzheimer's disease	Disease	MESH:D000544
20420844	151	153	AD	Disease	MESH:D000544
20420844	172	198	neurodegenerative disorder	Disease	MESH:D019636
20420844	230	238	dementia	Disease	MESH:D003704
20420844	278	290	amyloid beta	Gene	351
20420844	292	297	Abeta	Gene	351
20420844	344	346	AD	Disease	MESH:D000544
20420844	348	353	Abeta	Gene	351
20420844	462	464	AD	Disease	MESH:D000544
20420844	471	493	Caenorhabditis elegans	Species	6239
20420844	495	505	C. elegans	Species	6239
20420844	516	518	AD	Disease	MESH:D000544
20420844	520	525	human	Species	9606
20420844	526	531	Abeta	Gene	351
20420844	631	636	Abeta	Gene	351
20420844	671	680	paralysis	Disease	MESH:D010243
20420844	786	794	dementia	Disease	MESH:D003704
20420844	798	800	AD	Disease	MESH:D000544
20420844	854	859	human	Species	9606
20420844	884	886	AD	Disease	MESH:D000544
20420844	921	931	fluoxetine	Chemical	MESH:D005473
20420844	945	954	serotonin	Chemical	MESH:D012701
20420844	997	1002	Abeta	Gene	351
20420844	1011	1020	paralysis	Disease	MESH:D010243
20420844	1028	1038	C. elegans	Species	6239
20420844	1048	1053	Abeta	Gene	351
20420844	1054	1062	toxicity	Disease	MESH:D064420
20420844	1075	1080	Abeta	Gene	351
20420844	1138	1144	DAF-16	Gene	172981
20420844	1190	1200	fluoxetine	Chemical	MESH:D005473
20420844	1218	1227	paralysis	Disease	MESH:D010243
20420844	1248	1258	fluoxetine	Chemical	MESH:D005473
20420844	1348	1358	fluoxetine	Chemical	MESH:D005473
20420844	1397	1399	AD	Disease	MESH:D000544
20420844	1420	1434	proteotoxicity	Disease	
20420844	Negative_Correlation	MESH:D005473	MESH:D010243
20420844	Association	MESH:D005473	172981
20420844	Negative_Correlation	MESH:D005473	MESH:D012701
20420844	Association	MESH:D010243	172981
20420844	Association	MESH:D064420	351
20420844	Negative_Correlation	MESH:D005473	MESH:D000544
20420844	Association	MESH:D000544	351
20420844	Positive_Correlation	MESH:D010243	351
20420844	Negative_Correlation	MESH:D005473	351

